June 2022 Midatech Pharma PLC ( Midatech or the Company ) Directorate Change Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medic

Midatech Pharma PLC (AIM:

MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, is pleased

to announce the appointment of Dr Stephen Parker as a Director of the Company and Non-Executive Chairman of the Board with immediate effect.

Stephen Parker has over 30 years' experience

in leadership roles both in the healthcare industry and in advisory roles. Currently, he is Chairman of Sareum Holdings plc (AIM: SAR)

and Drishti Discoveries Ltd., a Non-Executive Director of MGC Pharmaceuticals Ltd (ASX,LSE: MXC) and an Executive Director of sp2

Consulting Limited. Previously, Stephen held a number of executive and board positions at various public and private biotech companies

and senior roles at leading investment banks. Stephen has an MBA from City University and a D.Phil. in biochemistry from Oxford University.

Dr Parker is taking over

from Rolf Stahel, who has resigned as a Director of the Company and stepped down as Chairman in line with his proposed retirement, previously

announced on 10 June 2022.

Additional Information

The following information is disclosed pursuant

to Schedule Two paragraph (g)of the AIM Rules for Companies in relation to Dr Stephen Barry Parker, aged 63:

Dr Parker was formerly

a director of Celtic Pharma Development UK Plc, Xenova Group Limited and Xenova Limited, each of which were subsidiaries of Celtic Pharma

GP Limited and were placed into creditors voluntary liquidation in April 2014.

As of the date of this

announcement, Dr Parker holds no ordinary shares or options in the Company.

Save as disclosed above,

there are no additional disclosures to be made in accordance with Schedule Two paragraph (g) of the AIM Rules for Companies.

For more information, please contact:

Strand Hanson Limited

(Nominated and Financial Adviser)

James Dance / Matthew

Chandler / Rob Patrick

Tel: +44 (0)20 7409 3494

Turner Pope Investments

(TPI) Ltd (Joint Broker)

Andrew Thacker / James Pope

Tel: +44 (0)20 3657 0050

IFC Advisory Limited

(Financial PR and UK Investor Relations)

Tim Metcalfe / Graham

Tel: +44 (0)20 3934 6630

Email: midatech@investor-focus.co.uk

Edison Group (US Investor Relations)

Tel: +1 (860) 573 9637

Email: afactor@edisongroup.com

About Midatech Pharma

Midatech Pharma PLC (dual listed on LSE AIM: MTPH;

and NASDAQ: MTP) is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The

Company combines approved and development medications with its proprietary and innovative drug delivery technologies, to provide compelling

products that have the potential to powerfully impact the lives of patients.

The Company has developed three in-house technology

platforms, each with its own unique mechanism to improve delivery of medications to sites of disease. All of the Company's technologies

have successfully entered human use in the clinic, providing important validation of the potential for each platform:

The platform nature of the technologies offers

the potential to develop multiple drug assets rather than being reliant on a limited number of programmes. Midatech's technologies

are supported by 36 patent families including 120 granted patents and an additional 70 patent applications. Midatech's headquarters and

R&D facility is in Cardiff, UK. For more information, please visit www.midatechpharma.com